Moreover, in pancreatic cancer models, Tregs indirectly suppress CD8+ T cell activation by restraining tumor-associated dendritic cell growth and immunogenicity, curtailing IFN release and impairing tumor control. The gene discussed is CD8A; the disease is neoplasm.